Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.41 |
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | AURKA | O14965 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 3/20 | 0.36 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1E | P28566 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19366817 | 0.88 | HTR2A (0.39) | HTR2AHTR2CAURKAKDRAURKB | |
| SCHEMBL26781033 | 0.84 | LMNA (0.42) | HTR2ACYP3A4AAK1 | |
| SCHEMBL18948445 | 0.80 | CYP3A4 (0.38) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL12299816 | 0.77 | P2RX3 (0.41) | HTR2ACYP3A4 | |
| SCHEMBL12828077 | 0.77 | AURKA (0.42) | HTR2AHTR2CAURKAKDRAURKB | |
| SCHEMBL13939587 | 0.77 | CYP3A4 (0.36) | HTR2AHTR2CCYP3A4CYP2D6TSHR | |
| SCHEMBL21859435 | 0.77 | P2RX3 (0.41) | KDR | |
| SCHEMBL12828156 | 0.77 | CYP3A4 (0.36) | CYP3A4CYP2D6TSHRCRHBPCYP2C19 | |
| SCHEMBL18068089 | 0.77 | CYP3A4 (0.36) | HTR2CAURKAKDRAURKBCYP3A4 | |
| SCHEMBL12235180 | 0.76 | P2RX3 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3458066-B1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME LLC (US) | 2023-05-03 | — | — | EP | disclosed |
| US-10780092-B2 | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190307753-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2019-10-10 | — | — | US | disclosed |
| US-20090227599-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307753-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | PDE2A, PDE3A, PDE5A | HTR2A 333/4885HTR2C 1317/4885AURKA 4399/4885 |
| US-10780092-B2 | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators | PDE2A, PDE3A, PDE5A | HTR2A 326/4885HTR2C 1288/4885AURKA 4392/4885 |
| US-20090227599-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | HTR2A 946/4885HTR2C 1022/4885AURKA 4820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.